Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications

Area of Science:

• Biochemistry
• Immunology
• Cardiovascular Medicine

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is crucial in regulating low-density lipoprotein receptor (LDLR) degradation, impacting plasma lipid levels and cardiovascular disease risk.
• PCSK9 also influences cancer by degrading major histocompatibility protein class I, reducing cytotoxic T cell infiltration and promoting tumor growth.
• PCSK9's role in both cardiovascular disease and cancer highlights its significance as a therapeutic target.

Purpose of the Study:

• To review the current understanding of PCSK9's role in cardiovascular disease and cancer pathogenesis.
• To focus on the regulation of PCSK9 expression and its diverse functions.
• To explore the molecular mechanisms underlying PCSK9-mediated substrate degradation.

Main Methods:

• Literature review of existing research on PCSK9.
• Analysis of PCSK9's impact on LDLR and major histocompatibility protein class I.
• Discussion of current therapeutic strategies and limitations, including monoclonal antibody therapy.

Main Results:

• PCSK9 inhibition effectively lowers LDL cholesterol and suppresses tumor growth by increasing LDLR and cell surface MHC-I levels.
• Current PCSK9-inhibiting therapies, while effective, are limited by high costs.
• The precise molecular mechanism of PCSK9-mediated substrate degradation remains incompletely understood.

Conclusions:

• PCSK9 is a key factor in cardiovascular disease and cancer, making it a significant therapeutic target.
• Further research into PCSK9's degradation mechanisms is needed to develop more cost-effective treatments.
• Understanding PCSK9 regulation and function is vital for advancing treatments for major global diseases.